Pharmacogenetic Labeling of FDA-Approved Drugs-Reference-Cited by-同舟云学术

Pharmacogenetic Labeling of FDA-Approved Drugs

Published:2018-08 Issue:4 Volume:3 Page:545-549
ISSN:2452-302X
Container-title:JACC: Basic to Translational Science
language:en
Short-container-title:JACC: Basic to Translational Science

Author:

Drozda Katarzyna,Pacanowski Michael A.,Grimstein Christian,Zineh Issam

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference10 articles.

1. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA;Lesko;Pharmacogenomics,2010

2. Code of Federal Regulations Title 21. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.57. Accessed March 20, 2018.

3. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis;Sanderson;Genet Med,2005

4. Estimation of the warfarin dose with clinical and pharmacogenetic data;Klein;N Engl J Med,2009

5. The Creating an Optimal Warfarin Nomogram (CROWN) Study;Perlstein;Thromb Haemost,2012

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiscale mapping of transcriptomic signatures for cardiotoxic drugs;Nature Communications;2024-09-11

2. Establishing a patient‐centered, multidisciplinary pharmacogenomics clinic in an academic health system: Successes, challenges, and future direction;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2023-08-25

3. DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases;Pharmaceutics;2023-08-15

4. Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia;Medicine;2023-07-28

5. Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy;Clinical Pharmacology & Therapeutics;2023-07-11